Journal of Affective Disorders
July 1, 2022
T. D. Hull, Matteo Malgaroli, A. Gazzaley et al.
59 citations
At-home ketamine-assisted therapy with remote monitoring produced rapid and significant improvements in depression and anxiety. Among 1247 patients, 62.8% showed at least 50% improvement on the depression scale and 62.9% on the anxiety scale, with remission rates of 32.6% and 31.3%, respectively. Deterioration was rare (0.9% for depression, 0.6% for anxiety). Three patient subpopulations emerged: those who improved steadily (79.3%), those with delayed improvement (9.3%), and a chronic group (11.4%) who were more likely to report dissociation at the fourth session. Side effects at the second session predicted delayed improvement. Only six patients discontinued early due to side effects or adverse events, indicating that screening and monitoring kept risks low.
Palliative & Supportive Care
January 21, 2025
Caroline Dorsen, Lola Noero, Michelle Knapp et al.
5 citations
Fifteen facilitators of naturalistic psychedelic groups in the United States described community as essential to every aspect of psychedelic work: from motivation to use psychedelics, through the dosing experience, to integrating lessons into daily life. Thematic analysis identified two overarching themes: the arc of healing through community (with subthemes of intention, the group journey experience, and integration) and naturally occurring psychedelic communities as group therapy (with subthemes of belonging, authenticity, corrective experience, trust, and touch). The findings suggest that existing knowledge about therapeutic group processes may help structure and optimize group psychedelic work. More research is needed on group size, composition, substance selection, facilitator training, and community integration. Psychedelic groups may provide benefits that individual work does not.
Journal of Medical Internet Research
June 17, 2026
Acacia C Parks, Amanda L Woodward, Robert D Henry et al.
A large analysis of 3,870 patients with moderate-to-severe depression, anxiety, or PTSD who used a telehealth program for at-home subcutaneous ketamine found significant symptom reductions after about six weeks. Depression scores on the PHQ-9 fell from 14.6 to 6.3, anxiety scores on the GAD-7 from 13.1 to 6.1, and PTSD scores on the PCL-5 from 46.7 to 27.5, all with large effect sizes. Over 80% of patients achieved a clinically meaningful improvement. Adverse events were low (2.8%-3.2%), and no serious complications occurred. The results suggest that supervised at-home subcutaneous ketamine is a safe and effective option that could expand access to rapid-acting treatment.
Acacia C Parks, Amanda L Woodward, Robert D Henry et al.
A telehealth-supervised at-home subcutaneous ketamine protocol for moderate-to-severe depression, anxiety, and PTSD was safe, feasible, and highly effective. Among 3,870 patients, symptom scores dropped from moderate-to-severe to mild or subthreshold ranges after about six weekly sessions: depression scores fell from 14.64 to 6.30, anxiety from 13.06 to 6.09, and PTSD from 46.7 to 27.5, with large effect sizes. Clinically meaningful improvement occurred in 80% to 84.6% of patients, depending on condition. Adverse events were low (2.8%–3.2%), and no serious complications were reported. The model offers a lower-cost, high-bioavailability alternative to in-clinic ketamine infusions.